PowderJect to start vaccine trial

PowderJect is to start clinical trials of a vaccine to combat hepatitis B as part of its continuing strategic alliance with GlaxoSmithKline.

PowderJect to start vaccine trial

PowderJect is to start clinical trials of a vaccine to combat hepatitis B as part of its continuing strategic alliance with GlaxoSmithKline.

Oxford-based PowderJect, through its subsidiary PowderJect Vaccines, will study the effectiveness of a DNA immunotherapeutic treatment to combat hepatitis B, the chronic viral infection.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited